Current Status of Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasms in Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Flow cytometric immunophenotyping of hematolymphoid neoplasms (FCI-HLN) is essential for diagnosis, classification, and minimal residual disease (MRD) monitoring. FCI-HLN is typically performed using in-house protocols, raising the need for standardization. Therefore, we surveyed the current status of FCI-HLN in Korea to obtain fundamental data for quality improvement and standardization. Methods: Eight university hospitals actively conducting FCI-HLN participated in our survey. We analyzed responses to a questionnaire that included inquiries regarding test items, reagent antibodies (RAs), fluorophores, sample amounts (SAs), reagent antibody amounts (RAAs), acquisition cell number (ACN), isotype control (IC) usage, positive/negative criteria, and reporting. Results: Most hospitals used acute HLN, chronic HLN, plasma cell neoplasm (PCN), and MRD panels. The numbers of RAs were heterogeneous, with a maximum of 32, 26, 12, 14, and 10 antibodies used for acute HLN, chronic HLN, PCN, ALL-MRD, and multiple myeloma-MRD, respectively. The number of fluorophores ranged from 4 to 10. RAs, SAs, RAAs, and ACN were diverse. Most hospitals used a positive criterion of 20%, whereas one used 10% for acute and chronic HLN panels. Five hospitals used ICs for the negative criterion. Positive/negative assignments, percentages, and general opinions were commonly reported. In MRD reporting, the limit of detection and lower limit of quantification were included. Conclusions: This is the first comprehensive study on the current status of FCI-HLN in Korea, confirming the high heterogeneity and complexity of FCI-HLN practices. Standardization of FCI-HLN is urgently needed. The findings provide a reference for establishing standard FCI-HLN guidelines.
Abstract
Background: Flow cytometric immunophenotyping of hematolymphoid neoplasms (FCI-HLN) is essential for diagnosis, classification, and minimal residual disease (MRD) monitoring. FCI-HLN is typically performed using in-house protocols, raising the need for standardization. Therefore, we surveyed the current status of FCI-HLN in Korea to obtain fundamental data for quality improvement and standardization. Methods: Eight university hospitals actively conducting FCI-HLN participated in our survey. We analyzed responses to a questionnaire that included inquiries regarding test items, reagent antibodies (RAs), fluorophores, sample amounts (SAs), reagent antibody amounts (RAAs), acquisition cell number (ACN), isotype control (IC) usage, positive/negative criteria, and reporting. Results: Most hospitals used acute HLN, chronic HLN, plasma cell neoplasm (PCN), and MRD panels. The numbers of RAs were heterogeneous, with a maximum of 32, 26, 12, 14, and 10 antibodies used for acute HLN, chronic HLN, PCN, ALL-MRD, and multiple myeloma-MRD, respectively. The number of fluorophores ranged from 4 to 10. RAs, SAs, RAAs, and ACN were diverse. Most hospitals used a positive criterion of 20%, whereas one used 10% for acute and chronic HLN panels. Five hospitals used ICs for the negative criterion. Positive/negative assignments, percentages, and general opinions were commonly reported. In MRD reporting, the limit of detection and lower limit of quantification were included. Conclusions: This is the first comprehensive study on the current status of FCI-HLN in Korea, confirming the high heterogeneity and complexity of FCI-HLN practices. Standardization of FCI-HLN is urgently needed. The findings provide a reference for establishing standard FCI-HLN guidelines.
참고문헌 (40)
- Glier H, "Standardization of 8-color flow cytometry across different flow cytometer instruments : a feasibility study in clinical laboratories in Switzerland", J Immunol Methods, 475, pp.112348~ (2019)
- Collective Publication. Panel proposal for the immunophenotypic diagnosis of hematological malignancies, "A collaborative consensus from the Groupe d’Étude Immunologique des Leucémies(GEIL)", Cytometry B Clin Cytom, 94, pp.542~547 (2018)
- CLSI, "Clinical flow cytometric analysis of neoplastic hematolymphoid cells" (2007), Clinical and Laboratory Standards Institute
- Solly F, "Standardization of flow cytometric immunophenotyping for hematological malignancies : the FranceFlow group experience", Cytometry A, 95, pp.1008~1018 (2019)
- Döhner H, "Diagnosis and management of AML in adults : 2022 recommendations from an international expert panel on behalf of the ELN", Blood, 140, pp.1345~1377 (2022)
- DiGiuseppe JA, "Applications of flow cytometric immunophenotyping in the diagnosis and posttreatment monitoring of B and T lymphoblastic leukemia", lymphoma, 2019, pp.96, 256~265
- Kumar S, "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma", Lancet Oncol, 17, pp.e328~e346 (2016)
- Rawstron AC, "A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia : an European research Initiative on CLL study", Leukemia, 30, pp.929~936 (2016)
- "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): multiple myeloma. version 3.2023, December 8, 2022" (2023)[URL]
- Riva G, "Multiparametric flow cytometry for MRD monitoring in hematologic malignancies : clinical applications and new challenges", Cancers, 13, pp.4582~ (2021)
- Maecker HT, "Standardizing immunophenotyping for the Human Immunology Project", Nat Rev Immunol, 12, pp.191~200 (2012)
- Soh KT, "Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease", Cytometry B Clin Cytom, 98, pp.161~173 (2020)
- Diks AM, "Impact of blood storage and sample handling on quality of high dimensional flow cytometric data in multicenter clinical research", J Immunol Methods, 475, pp.112616~ (2019)
- Cardoso CC, "Eight-color panel for immune phenotype monitoring by flow cytometry", J Immunol Methods, 468, pp.40~48 (2019)
- Kalina T, "Reproducibility of flow cytometry through standardization : opportunities and challenges", Cytometry A, 97, pp.137~147 (2020)
- Kalina T, "EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols", Leukemia, 26, pp.1986~2010 (2012)
- Theunissen P, "Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia", Blood, 129, pp.347~357 (2017)
- Wang L, "Standardization, calibration, and control in flow cytometry", Curr Protoc Cytom, 79, pp.1.3.1~1.3.27 (2017)
- Lhermitte L, "Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia : a EuroFlow study", Mod Pathol, 34, pp.59~69 (2021)
- Le Lann L, "PRECISESADS Clinical Consortium Standardization procedure for flow cytometry data harmonization in prospective multicenter studies", Sci Rep, 10, pp.11567~ (2020)
- Mizrahi O, "Quantitative flow cytometry : concerns and recommendations in clinic and research", Cytometry B Clin Cytom, 94, pp.211~218 (2018)
- Van Dongen JJ, "EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes", Leukemia, 26, pp.1908~1975 (2012)
- Stetler-Stevenson M, "Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition", Cytometry B Clin Cytom, 90, pp.26~30 (2016)
- Foureau DM, "Standardizing clinical workflow for assessing minimal residual disease by flow cytometry in multiple myeloma", Clin Lymphoma Myeloma Leuk, 23, pp.e41~e50 (2023)
- Arroz M, "Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting", Cytometry B Clin Cytom, 90, pp.31~39 (2016)
- Khoury JD, "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours : Myeloid and Histiocytic", Dendritic Neoplasms, 2022, pp.36, 1703~1719
- Chan RC, "Stabilization of pre-optimized multicolor antibody cocktails for flow cytometry applications", Cytometry B Clin Cytom, 92, pp.508~524 (2017)
- Verschoor CP, "An introduction to automated flow cytometry gating tools and their implementation", Front Immunol, 6, pp.380~ (2015)
- Salem DA, "Clinical flow-cytometric testing in chronic lymphocytic leukemia", Methods Mol Biol, 2032, pp.311~321 (2019)
- Choi Y, "Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia : a multicenter retrospective study", Korean J Intern Med, 36, pp.194~204 (2021)
- Kim HY, "Clinical utility of next-generation flow-based minimal residual disease assessment in patients with multiple myeloma", Ann Lab Med, 42, pp.558~565 (2022)
- Sommer U, "High-sensitivity flow cytometric assays : considerations for design control and analytical validation for identification of rare events", Cytometry B Clin Cytom, 100, pp.42~51 (2021)
- Heuser M, "2021 Update on MRD in acute myeloid leukemia : a consensus document from the European LeukemiaNet MRD Working Party", Blood, 138, pp.2753~2767 (2021)
- CLSI, "Validation of assays performed by flow cytometry" (2021), Clinical and Laboratory Standards Institute
- Bene MC, "Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)", Leukemia, 9, pp.1783~1786 (1995)
- Maecker HT, "Flow cytometry controls, instrument setup, and the determination of positivity", Cytometry A, 69, pp.1037~1042 (2006)
- van den Ancker W, "A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin", Cytometry B Clin Cytom, 84, pp.114~118 (2013)
- Guy J, "Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia", Br J Haematol, 161, pp.551~555 (2013)
- Manivannan P, "Can threshold for MPO by flow cytometry be reduced in classifying acute leukaemia? A comparison of flow cytometric and cytochemical myeloperoxidase using different flow cytometric cut-offs", Hematology, 20, pp.455~461 (2015)
- Szalóki G, "Compensation in multicolor flow cytometry", Cytometry A, 87, pp.982~985 (2015)